RXi Pharmaceuticals Corporation, an RNA-targeted technologies company, today announced positive results from their second placebo-controlled Phase 1 study with RXI‑109, an sd-rxRNA compound that targets Connective Tissue Growth Factor (CTGF), and is being developed for the treatment of abnormal dermal scars such as hypertrophic scars and keloids in conjunction with scar revision surgery.
In this study, subjects received small skin incisions in their abdomen and were treated with 3 intradermal doses of RXI‑109 over a 2-week period. This dose escalating study consisted of 3 cohorts of 3 healthy volunteers each. Subjects received RXI‑109 on one side of the abdomen, and placebo on the other side.
Subjects were monitored for safety and local and systemic side effects over a total study period of 84 days.
Multiple dermal injections were well tolerated at all doses and treatment with RXI‑109 resulted in dose-dependent silencing of CTGF mRNA in the treated areas.
Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals said that, "We are very pleased with the outcome of this second Phase 1 study. These results show that multiple intradermal injections of RXI‑109 are well tolerated with minimal and mild side effects. He added that, "The work done in the last year has confirmed that our proprietary self-delivering RNAi technology (sd-rxRNA) reduces CTGF mRNA in humans in line with its mechanism of action. Indeed, results from this second study demonstrate that mRNA for CTGF in the incisions is reduced in a dose-dependent manner by RXI‑109 as compared to placebo. Our first Phase 1 study had already shown that a single dose of the drug lowered the actual protein content for CTGF also in a dose-dependent manner. With this exciting outcome, we are ready to embark on Phase 2 development in patients with hypertrophic scars and keloids."
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- How A Former Naturopath Can Help Unravel The Trickery of Alternative Medicine
- Swarm Bots Kill Mass Shooter
- Can A New Rule Trigger A Second EU Referendum? Petition 4 Millon Signatures, Nearly 12% Of Total Votes Cast
- Nanotech: The Most Dangerous Science Least Carefully Done
- A Billion Years Ago, What Did Earth's Ancient Magnetic Field Look Like?
- Finding All-Hadronic Top - Again
- Did Controversy Over Statins Influence Their Use In The UK?
- "A scientific approach is the only way one can really be assured that a treatment has merits. The..."
- "Bollocks! You will find the possible side effects listed are a exhaustive precautionary list of..."
- "Sorry, but even using the term allopath shows your bias. That is a term invented by the creator..."
- "Lets make something clear- most of you are arguing past each other on topics that are too broad..."
- "Hi Anlain, it explains on the page itself. It's a post vote survey - not a poll, so more accurate..."
- Why Some Sounds Make Us Cringe
- Over 100 Nobel Laureates Condemn Greenpeace for Opposing Golden Rice
- New Team Member: Dr. Alex Berezow
- DIY Biohacking: Unethical, Fringe and Probably Necessary to Advance Science
- Summer Camp Means Fun for Kids, But Panic for Some Parents
- Swayed By Lunch Money: A Grotesque Insult to Doctors
- Cannabinoids remove plaque-forming Alzheimer's proteins from brain cells
- NIH-supported study pinpoints origin of 2009 H1N1 influenza pandemic
- The July 2016 issue of Geology is now online
- At the droplet of a hat: Capturing mixable liquid interaction
- Triple external quantum efficiencies -- a new material TADF was developed